Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895245 · ClinicalTrials.gov registry record · Phase 2
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00895245 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 6 participants.
The verdict
NCT00895245, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
Interventions
- DRUG cisplatin
- DRUG dexamethasone
- DRUG palonosetron hydrochloride
- DRUG fosaprepitant dimeglumine
- OTHER Functional Living Index-Emesis Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00895245
The ClinicalTrials.gov registry entry for NCT00895245 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00895245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00895245 about?
NCT00895245 is a clinical study titled "Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy". RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant...
What is the current status of trial NCT00895245?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2009-02. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00895245?
The interventions under investigation include: cisplatin (DRUG), dexamethasone (DRUG), palonosetron hydrochloride (DRUG), fosaprepitant dimeglumine (DRUG), Functional Living Index-Emesis Questionnaire (OTHER).
Who is sponsoring clinical trial NCT00895245?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.